Provided by Tiger Trade Technology Pte. Ltd.

Cohen & Steers

74.95
-1.7100-2.23%
Post-market: 75.000.0500+0.07%19:30 EDT
Volume:360.83K
Turnover:27.22M
Market Cap:3.85B
PE:23.06
High:78.48
Open:77.76
Low:74.74
Close:76.66
52wk High:86.56
52wk Low:58.39
Shares:51.39M
Float Shares:27.75M
Volume Ratio:1.37
T/O Rate:1.30%
Dividend:2.58
Dividend Rate:3.44%
EPS(TTM):3.25
EPS(LYR):2.97
ROE:27.33%
ROA:14.54%
PB:6.54
PE(LYR):25.24

Loading ...

Takeda’s TAK-360 Narcolepsy Trial Moves Forward, Expanding Its Specialty CNS Pipeline

TIPRANKS
·
Jun 10

Cohen & Steers Income Opportunities REIT acquires 1890 Ranch shopping center near Austin, Texas

Reuters
·
Jun 09

Cohen & Steers Posts Lower Preliminary Assets Under Management in May

MT Newswires Live
·
Jun 09

Cohen & Steers Quality Income Realty Fund sets USD 0.09 monthly distribution for July-September 2026

Reuters
·
Jun 09

Cohen & Steers RQI issues transferable share rights for common stock offering

Reuters
·
Jun 09

Cohen & Steers Quality Income Realty Fund, Inc. Announces Terms of Transferable Rights Offering

THOMSON REUTERS
·
Jun 09

Cohen & Steers - Reports Preliminary Aum of $99.5 Bln as of May 31, 2026

THOMSON REUTERS
·
Jun 09

Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2026

THOMSON REUTERS
·
Jun 09

Cohen & Steers price target raised to $82 from $76 at Evercore ISI

TIPRANKS
·
Jun 08

Assessing Cohen & Steers (CNS) Valuation As Shares Show Recent Momentum

Simply Wall St.
·
Jun 08

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 05

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

GlobeNewswire
·
Jun 05

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

GlobeNewswire
·
Jun 04

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

GlobeNewswire
·
Jun 04

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

GlobeNewswire
·
Jun 03

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 03

CNSREIT acquires Sprouts-anchored shopping center in Arizona

TIPRANKS
·
Jun 02

Inswave Systems Wins Web Terminal Switching Contract from LG CNS

MT Newswires Live
·
Jun 02

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

GlobeNewswire
·
Jun 01

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

GlobeNewswire
·
Jun 01